Different targets
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity. Cagrilintide acts through the amylin pathway and is not a GLP-1 agonist.
Plain-English research guide
GLP-related pathways,
compared carefully.
This compares mechanisms and research status. It does not compare products, recommend treatment or establish that one option is better for any person.CompoundPrimary targetResearch stageCommon measured endpoints
TirzepatideGIP + GLP-1Large human clinical-trial evidence; regulated prescription formulations existGlycemic, body-weight, metabolic, cardiovascular and kidney-related endpointsRetatrutideGIP + GLP-1 + glucagonInvestigational; clinical trials ongoingBody-weight, glycemic, metabolic, liver, cardiovascular and kidney endpointsCagrilintideAmylin pathway — not a GLP-1 agonistInvestigational; studied alone and with GLP-1-related agentsAppetite-related, body-weight and metabolic endpointsDifferent evidence stages
Tirzepatide has extensive controlled human evidence and regulated formulations. Retatrutide and cagrilintide remain investigational.
No personal conclusion
Different trial populations, formulations and endpoints prevent a simple “best” conclusion. A healthcare professional is the appropriate source for personal medical decisions.